



MSB  
K  
2-20-02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Gerhard Siemeister et al.

Group Art Unit: To Be Assigned

Serial No.: 09/887,527

Examiner: To Be Assigned

Filed: June 25, 2001

For: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH  
VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND  
THEIR USE

**SUPPLEMENTAL PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

**IN THE CLAIMS:**

B<sup>2</sup>  
13. (Twice Amended) Pharmaceutical compositions according to claim 1 which comprise as compound I and/ or II Seq. ID Nos. 60.

B<sup>3</sup>  
17. (Twice Amended) Pharmaceutical compositions according to claim 1 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

I hereby certify that this correspondence is being deposited  
with the U.S. Postal Services as First Class Mail in an envelope  
and To: Commissioner of Patents and Trademarks,  
Washington, D.C. 20231 On: 10/22/01

Debra T. Johnson  
10/22/01